Objectives While exercise adherence is known to vary during cancer treatment, little is known about what predicts these changes during chemotherapy or within individual treatment cycles for breast cancer. We examined changes in adherence and its predictors (1) across chemotherapy treatment and (2) within treatment cycles in women undergoing (neo-)adjuvant chemotherapy for breast cancer.
Design This study is based on data from the Phys-Can multicentre parallel randomised trial. Setting The exercise intervention was conducted at public gyms in three Swedish university cities.
Participants 178 women undergoing (neo-)adjuvant chemotherapy without any chemotherapy treatment delays and had any adherence data were included in the analysis. Interventions Participants in the Phys-Can trial were randomised to either high or low-to-moderate intensity combined endurance and resistance training.
Primary outcome The primary outcome variable for this secondary analysis of Phys-Can trial data was adherence to endurance and resistance training. Bayesian multilevel growth curve models were used to examine adherence to resistance and endurance training throughout the chemotherapy treatment period and within chemotherapy cycles.
BMJ Open published a clinical update in Research Highlights on 07 May 2026.
The item focuses on What is the adherence to an exercise intervention during (neo-)adjuvant chemotherapy among Swedish patients with breast cancer?
Data from the Phys-Can randomised controlled trial.
Review the original article for the full source wording and details.